Xiao-Lei Xu

Patterns of IgG and IgM antibody response in COVID-19 patients

Xuemei Liu, Jing Wang, Xiao-Lei Xu et al. · Emerging Microbes & Infections · 2020 · 256 citations · Full text

Life Sciences, Immunology, Infectious Diseases +8

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol

Yanming Zeng, Xiao-Lei Xu, Xiaoqing He et al. · Chinese Medical Journal · 2020 · 64 citations · Full text

Veterinary Medicine, Infectious Diseases, Internal Medicine +13

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

Yin-Qiu Huang, Shengquan Tang, Xiao-Lei Xu et al. · Frontiers in Pharmacology · 2020 · 55 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

The impact of COVID-19 on gastric cancer surgery: a single-center retrospective study

Yuxuan Li, Changzheng He, Yichen Liu et al. · BMC Surgery · 2020 · 24 citations · Full text

Medicine, Oncology, Surgery +11

Establishment of a novel scoring model for mortality risk prediction in HIV-infected patients with cryptococcal meningitis

Ting Zhao, Xiao-Lei Xu, Zhongsheng Jiang et al. · BMC Infectious Diseases · 2021 · 14 citations · Full text

Veterinary Medicine, Infectious Diseases, Epidemiology +16